Erratum

The acknowledgement included in the below-noted article was incomplete as published. The complete acknowledgement appears below.

White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, McDonough JH, Stables JP, Kaufmann D, Yagen B, Bialer M. (2012) A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia. 53(1): 134–146. [doi: 10.1111/j.1528-1167.2011.03338.x. Epub 2011 Dec 9].

Acknowledgments

Studies conducted at the University of Utah were supported by NINDS and the NIH Office of the Director CounterACT Program, NIH Contract No. NO1-NS-4-2359 (HSW, ABA, KSW, ALP). The studies conducted at MRICD were supported by an Inter-Agency Agreement between NIH/NIAID (Y1-O6-9613-01) and USAMRICD (A120-B.P2009-2) and the Defense Threat Reduction Agency – Joint Science and Technology Office, Medical S&T Division. The views expressed in this paper are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, or the U.S. Government.